Assure — Investor Presentation (September 2023)
18 slides from Assure's investor presentation, Sep 20, 2023
Slide 1: Investor Presentation September 2023
Investor Presentation September 2023 | NASDAQ: IONM
Slide 2: Cautionary Note regarding Forward-Looking Statements
Cautionary Note regarding Forward - Looking Statements This presentation may contain “forward - looking statements” within the meaning of applicable securities laws. Forward - looking sta tements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "shoul
Slide 3: Who We Are
Who We Are Assure Neuromonitoring | 3 1 https:// www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/ionm / Assure Operations Providing technical and professional medical services Assure Holdings is a healthcare services company providing best - in - class, outsourced Intraoperative Neuro
Slide 4: Company Overview
Company Overview A telehealth remote neurology services company with exceptional capabilities in IONM Supporting a growing network of providers Best in class outsourced IONM provider M&A Successful record of being a consolidator of the market Assure Neuromonitoring | 5 Opportunities for Vertical E x
Slide 5: IONM Market Overview
• Real time observation & analysis of neural structures during surgery • IONM regarded as standard of care in the U.S. • Est. $2B U.S. market growing at 10% • Highly fragmented industry IONM Market Overview Assure Neuromonitoring | 6 * See Safe Harbor for definition of managed cases What Why When •
Slide 6: Assure Platform
Assure Neuromonitoring | 7 Assure Platform Clinical Operations Revenue Cycle Mgmt. Managed Care Business Operations Accounting/Finance Training & Development M&A IONM Remote Neurology Services Spine Neurosurgery Vascular ENT Orthopedic IONM EEG Epilepsy Sleep Study Stroke Legacy Verticals Vertical O
Slide 7: Competitive Landscape
Assure Neuromonitoring | 10 Competitive Landscape Provider Estimated Number of 202 2 IONM Surgeries Dedicated Technologist IONM Specific Company Professional Oversight on 100% of Cases 100% of Technologists Board Certified In House Patient Advocate Team Provides Remote Neurology Services Cost Saving
Slide 8: 2023 Corporate Objectives
2023 Corporate Objectives Explore Strategic Alternatives In - Network Agreements Cash Collections Clinical Leadership • Board of Directors initiated a process to explore strategic alternatives in September 2023 • Evaluating a broad range of options • No assurance the review will result in pursuing o
Slide 9: 2022 Financial Results
2022 Financial Results Gross to Net Revenue ($m) Adj. EBITDA ** ($m) Assure Neuromonitoring | 12 ** See reconciliations of non - GAAP results in the Appendix and the explanation of Non - GAAP Financial Measures in the cautionary notes Net Loss ($m) • Downward pressure on reimbursement across the ind
Slide 10: Six Months Ended June 30, 2023 Financial Results
Six Months Ended June 30, 2023 Financial Results Gross to Net Revenue ($m) Adj. EBITDA ** ($m) Assure Neuromonitoring | 12 ** See reconciliations of non - GAAP results in the Appendix and the explanation of Non - GAAP Financial Measures in the cautionary notes Net Loss ($m) • Downward pressure on re
Slide 11: Significance of Cash Receipts
2021 2022 2023 2021 2022 2023 2021 2022 2023 $1.9 $2.4 $2.1 $3.5 $4.2 $4.6 $4.5 $3.3 $3.8 $4.2 T6M DOS Collected – by Quarter Assure Neuromonitoring | 13 Significance of Cash Receipts Cash collection is primary factor impacting accrual rate, bad debt, earnings and value of the business Collecting ~6
Slide 12: Summary Balance Sheets and Cap Table
Summary Balance Sheets and Cap Table R aised $6 million in equity offering in May 2023 Assure Neuromonitoring | 14 * Related to convertible debt, private placement and credit facility issuances Cap Table As of June 30, 2023 Outstanding shares 5,422,014 Outstanding warrants 194,974 Outstanding stock
Slide 13: Seasoned Management Team
Beth Lindstrom VP, Clinical Operations Sherri Wagner VP, Human Resources Paul Webster SVP, Revenue Cycle & Managed Care John Price Chief Financial Officer Seasoned Management Team Assure Neuromonitoring | 15 John Farlinger Executive Chairman & CEO Jerod Powell Chief Information Officer
Slide 14: Accomplished Board of Directors
Accomplished Board of Directors ■ 25 + years of technology, operations and capital markets experience ■ Former Chair and CEO of Urban Communications, CEO of Titan Communications and Adzilla ■ Drove multiple corporate exits John A. Farlinger, CPA CA (Chair) ■ 20+ years of experience as a board - cert
Slide 15: Contact Us
Contact Us Assure Holdings 7887 E. Belleview Ave., Suite 500, Denver, CO (720) 617 - 2526 www.assureneuromonitoring.com Company Contact John Farlinger Executive Chairman and CEO John.Farlinger@assureiom.com Investor Relations Assure Neuromonitoring | 18
Slide 16: Appendix
SSURE (Gesu Appendix NASDAQ: |ONM
Slide 17: SURGEONS HOSPITALS INSURANCE PATIENTS x Under - trained IONM technologists x Lack of continuity
SURGEONS HOSPITALS INSURANCE PATIENTS x Under - trained IONM technologists x Lack of continuity and trust with technologists x Burdened with operational services x Limited opportunity to benefit from revenue share x Patient care and liability issues x IONM treated as non - core competency x Costly b
Slide 18: Non-GAAP Financial Measures Reconciliation
Non - GAAP Financial Measures Reconciliation Assure Neuromonitoring | 21 Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 (unaudited) (unaudited) (unaudited) (unaudited) EBITDA Net loss ($ 5,262) ($ 4,726) ($ 9,576) ($ 7,185) Interest expense 509 439 1,018 846 Accretion expe
Assure Holdings — Investor Presentation (September 2023) on 6ix